UroGen says USPTO allows new patent claims for ZUSDURI, UGN-103 through July 2044
URGN•Clinical data supports claims
The claims are supported by data from the ENVISION and ATLAS clinical trials, strengthening the company’s IP position in non-surgical bladder cancer therapy.
USPTO allowance for UroGen patent application
UroGen Pharma received a USPTO notice of allowance for a U.S. patent application covering mitomycin RTGel-based treatment methods for recurrent LG-IR-NMIBC without TURBT.
Patent term expected to extend through July 2044
The patent, once issued, is expected to expire in July 2044, extending protection for ZUSDURI and the UGN-103 program.
